OBJECTIVES: To identify a molecular profile for schizophrenia using post-mortem pituitaries from schizophrenia and control subjects. METHODS: Molecular profiling analysis of pituitaries from schizophrenia (n = 14) and control (n = 15) subjects was carried out using a combination of liquid chromatography tandem mass spectrometry (LC-MS(E)), multiplex analyte profiling (MAP), two-dimensional difference gel electrophoresis (2D-DIGE) and Western blot analysis. RESULTS: This led to identification of differentially expressed molecules in schizophrenia patients including hypothalamic-pituitary-adrenal axis-associated constituents such as cortisol, pro-adrenocorticotropic hormone, arginine vasopressin precursor, agouti-related protein, growth hormone, prolactin and secretagogin, as well as molecules associated with lipid transport and metabolism such as apolipoproteins A1, A2, C3 and H. Altered levels of secretagogin in serum from a cohort of living first onset schizophrenia patients were also detected, suggesting disease association and illustrating the potential for translating some components of this molecular profile to serum-based assays. CONCLUSIONS: Future studies on the molecules identified here may lead to new insights into schizophrenia pathophysiology and pave the way for translation of novel diagnostics for use in a clinical setting.
OBJECTIVES: To identify a molecular profile for schizophrenia using post-mortem pituitaries from schizophrenia and control subjects. METHODS: Molecular profiling analysis of pituitaries from schizophrenia (n = 14) and control (n = 15) subjects was carried out using a combination of liquid chromatography tandem mass spectrometry (LC-MS(E)), multiplex analyte profiling (MAP), two-dimensional difference gel electrophoresis (2D-DIGE) and Western blot analysis. RESULTS: This led to identification of differentially expressed molecules in schizophreniapatients including hypothalamic-pituitary-adrenal axis-associated constituents such as cortisol, pro-adrenocorticotropic hormone, arginine vasopressin precursor, agouti-related protein, growth hormone, prolactin and secretagogin, as well as molecules associated with lipid transport and metabolism such as apolipoproteins A1, A2, C3 and H. Altered levels of secretagogin in serum from a cohort of living first onset schizophreniapatients were also detected, suggesting disease association and illustrating the potential for translating some components of this molecular profile to serum-based assays. CONCLUSIONS: Future studies on the molecules identified here may lead to new insights into schizophrenia pathophysiology and pave the way for translation of novel diagnostics for use in a clinical setting.
Authors: C W Holtzman; H D Trotman; S M Goulding; A T Ryan; A N Macdonald; D I Shapiro; J L Brasfield; E F Walker Journal: Neuroscience Date: 2013-01-05 Impact factor: 3.590
Authors: Hans-Gert Bernstein; Susan Müller; Hendrik Dobrowolny; Carmen Wolke; Uwe Lendeckel; Alicja Bukowska; Gerburg Keilhoff; Axel Becker; Kurt Trübner; Johann Steiner; Bernhard Bogerts Journal: Eur Arch Psychiatry Clin Neurosci Date: 2016-12-29 Impact factor: 5.270
Authors: Gregg W Crabtree; Ziyi Sun; Mirna Kvajo; Jantine A C Broek; Karine Fénelon; Heather McKellar; Lan Xiao; Bin Xu; Sabine Bahn; James M O'Donnell; Joseph A Gogos Journal: J Neurosci Date: 2017-03-10 Impact factor: 6.167
Authors: Hendrik Wesseling; Man K Chan; T M Tsang; Agnes Ernst; Fabian Peters; Paul C Guest; Elaine Holmes; Sabine Bahn Journal: Neuropsychopharmacology Date: 2013-07-03 Impact factor: 7.853
Authors: Paul C Guest; Keiko Iwata; Takahiro A Kato; Johann Steiner; Andrea Schmitt; Christoph W Turck; Daniel Martins-de-Souza Journal: Front Cell Neurosci Date: 2015-05-12 Impact factor: 5.505
Authors: Robert E Lin; Lauren Ambler; Eddie N Billingslea; Jimmy Suh; Shweta Batheja; Valerie Tatard-Leitman; Robert E Featherstone; Steven J Siegel Journal: Physiol Rep Date: 2013-10-20